{"DataElement":{"publicId":"6306950","version":"1","preferredName":"Inotuzumab Ozogamicin Cycle Count Administered Day Count","preferredDefinition":"The number of days the inotuzumab ozogamicin cycles were administered.","longName":"6306931v1.0:2018594v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6306931","version":"1","preferredName":"Inotuzumab Ozogamicin Cycle Count Administered","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._To determine the number or amount of something; the result of this activity._The act of having given something (e.g., a medication or test).","longName":"5724182v1.0:3988131v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5724182","version":"1","preferredName":"Inotuzumab Ozogamicin","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"C71542","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B52C4CB-AE3E-627C-E053-F662850A0E20","latestVersionIndicator":"Yes","beginDate":"2017-03-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-22","modifiedBy":"ONEDATA","dateModified":"2017-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3988131","version":"1","preferredName":"Cycle Count Administered","preferredDefinition":"An event or sequence of events that constitute round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.:To determine the number or amount of something; the result of this activity.:The act of having given something (e.g., a medication or test).","longName":"C25472:C25463:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED47A259-1D94-BCB3-E040-BB89AD4307AB","latestVersionIndicator":"Yes","beginDate":"2013-12-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-12-11","modifiedBy":"ONEDATA","dateModified":"2013-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D6B7072-D0CB-5BA2-E053-F662850AA139","latestVersionIndicator":"Yes","beginDate":"2018-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-30","modifiedBy":"KUMMEROA","dateModified":"2018-08-15","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018594","version":"1","preferredName":"Day Count","preferredDefinition":"the quantity of days.","longName":"D_CT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2207941","version":"1","preferredName":"Day Count","preferredDefinition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours.:To determine the number or amount of something; the result of this activity.","longName":"C25301:C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-35FE-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66ACE83-B97C-5040-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"CAMPBELB","dateModified":"2017-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What were the number of days","type":"Preferred Question Text","description":"What were the number of days the inotuzumab ozogamicin cycles were administered?","url":null,"context":"NHLBI"},{"name":"Length of cycle:","type":"Alternate Question Text","description":"Length of cycle:","url":null,"context":"NHLBI"},{"name":"Length of cycle:","type":"Application Standard Question Text","description":"Length of cycle:","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D6BA8BB-33E6-5B86-E053-F662850A945D","latestVersionIndicator":"Yes","beginDate":"2018-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-30","modifiedBy":"KUMMEROA","dateModified":"2018-08-15","changeDescription":". System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}